The reason is that the performance of alternative G-CSF schedules is difficult to predict in view of the strong interaction of chemotherapy-induced leukopenia, pharmacokinetic properties of G-CSF and the resulting effects on bone marrow leukopoiesis. This evidence concerns the gene CSF3 and Decreased total leukocyte count.